Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab (SUSTAIN)

• ClinicalTrials.gov Identifier: NCT02881567
• Recruitment Status: Terminated
• First Posted: August 29, 2016
• Results First Posted: September 24, 2019
• Last Update Posted: September 27, 2019
• Sponsor: Biogen
• Collaborator: AbbVie
• Information provided by (Responsible Party): Biogen

Study Description

Brief Summary:

The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched from treatment with natalizumab to daclizumab due to safety concerns. The secondary objectives of this study in this study population are to evaluate the effects of daclizumab on the following: 1) Multiple Sclerosis (MS) relapse activity including the annualized relapse rate (ARR) and the proportion of participants experiencing relapses requiring hospitalization and/or steroid treatment; 2) MS-related outcomes measured using magnetic resonance imaging (MRI); 3) Safety and tolerability in participants previously treated with natalizumab.

Condition or disease	Intervention/treatment	Phase
Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: Daclizumab	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 41 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)
• Actual Study Start Date: April 18, 2017
• Actual Primary Completion Date: September 12, 2018
• Actual Study Completion Date: September 12, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: Daclizumab	Drug: Daclizumab; High yield formulation; Other Names: BIIB019; Zinbryta

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants Relapse-free at Month 6 [ Time Frame: Month 6 ]
   Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist. The Kaplan-Meier estimate of the percentage of participants relapse-free at Month 6 is reported.

Secondary Outcome Measures :

1. Percentage of Participants Relapse-free at Month 12 [ Time Frame: Month 12 ]
   Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist.
2. Percentage of Participants Experiencing Relapse Requiring Hospitalization and/or Steroid Treatment at Month 12 [ Time Frame: Month 12 ]
   Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist.
3. Annualized Relapse Rate (ARR) at Month 12 [ Time Frame: Month 12 ]
   Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist. The ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of Month 12, and the ratio then multiplied by 365.
4. Number of Participants With New Gadolinium-Enhanced (Gd+) and T1 Hypointense Lesions at Months 6 and 12 [ Time Frame: Months 6 and 12 ]
   New Gadolinium-Enhanced (Gd+) and T1 Hypointense Lesions were assessed using magnetic resonance imaging (MRI).
5. Number of Participants With New and Newly Enlarged T2 Hypointense Lesions at Months 6 and 12 [ Time Frame: Months 6 and 12 ]
   New and newly enlarged T2 Hypointense Lesions were measured by MRI.
6. Permanent Discontinuation Rate of Daclizumab at Month 12 [ Time Frame: Month 12 ]
   Permanent Discontinuation Rate was calculated as the ratio of number of participants who had permanently discontinued daclizumab prior to Month 12 over the total number of participants who received at least 1 dose of daclizumab in the study.
7. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: First dose of study drug to within 30 days of last dose (up to 11 months) ]
   An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death or in the view of the Investigator, places the participant at immediate risk of death or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability or results in a birth defect.
8. Number of Participants With Clinically Relevant Shifts in Laboratory Assessments [ Time Frame: First dose of study drug to within 30 days of last dose (up to 11 months) ]
   Clinical Laboratory assessments were tests of Chemistry and Hematology. The investigator determined if any of the laboratory results were clinically relevant shifts from Baseline.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Key Inclusion Criteria

• Must have documented diagnosis of RRMS (McDonald 2010 Criteria) at screening [Polman 2011].
• Must have been treated with natalizumab for at least the 12 months prior to screening and have not missed 2 or more consecutive scheduled doses.
• Must be naïve to daclizumab and other forms of daclizumab such as Zenapax® prior to enrollment.
• Must have a confirmed Expanded Disability Status Scale (EDSS) score of 0 to 5.5, inclusive, at screening.
• Female participants of childbearing potential must practice effective contraception from Day -1 and be willing and able to continue contraception for duration of the study.

Key Exclusion Criteria

• Current participation in another investigational study.
• Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold) [Lublin 2014].
• Females breastfeeding, pregnant, or planning to become pregnant; or women who have a positive pregnancy test result during screening.
• History of drug or alcohol abuse (as defined by the Investigator) within 1 year prior to screening.
• History of severe hypersensitivity (e.g., anaphylaxis or anaphylactoid reactions) to the active ingredient or any of the excipients.
• History of severe opportunistic infections (including progressive multifocal leukoencephalopathy (PML)) or any clinically significant, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (other than MS), dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator.
• Discontinued natalizumab due to suspicion of PML.
• Known active malignancies (participants with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).
• The participant is using another MS therapy concomitantly.
• Known history of human immunodeficiency virus (HIV).
• Positive test result for Hepatitis C virus (test for hepatitis C virus antibody [HCV Ab]) or hepatitis B virus (test for hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody [HBcAb]).
• The participant has been treated with immunosuppressive or immunomodulating treatments including mitoxantrone, azathioprine, methotrexate, cyclophosphamide, or mycophenolate mofetil.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Contacts and Locations

Locations

United States, Florida

Research Site

Tampa, Florida, United States, 33612

United States, Iowa

Research Site

Des Moines, Iowa, United States, 50314

United States, Wisconsin

Research Site

Milwaukee, Wisconsin, United States, 53501

Canada, Alberta

Research Site

Edmonton, Alberta, Canada, T6G 2G3

Germany

Research Site

Muenchen, Bayern, Germany, 81675

Research Site

Potsdam, Brandenburg, Germany, 14471

Research Site

Dresden, Sachsen, Germany, 01307

Research Site

Hamburg, Germany, 20249

Italy

Research Site

Pozzilli, Isernia, Italy, 86077

Research Site

Napoli, Italy, 80131

Puerto Rico

Research Site

Guaynabo, Puerto Rico, 00968

Sponsors and Collaborators

Biogen

AbbVie

Investigators

• Study Director: Medical Director; Biogen

  Study Documents (Full-Text)

Documents provided by Biogen:

Statistical Analysis Plan  [PDF] June 14, 2018

Study Protocol  [PDF] July 6, 2016

More Information

• Responsible Party: Biogen
• ClinicalTrials.gov Identifier: NCT02881567
• Other Study ID Numbers: 205MS305; 2016-002820-10 ( EudraCT Number )
• First Posted: August 29, 2016
• Results First Posted: September 24, 2019
• Last Update Posted: September 27, 2019
• Last Verified: September 2019

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Biogen:

Multiple Sclerosis; Daclizumab; Tysabri-Switch

Additional relevant MeSH terms:

Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sclerosis; Pathologic Processes; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Daclizumab; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs